AB Corporate Bond ETF - EYEG STOCK NEWS

ReNeuron reported its H123 interim results, showcasing a significant revenue increase to £438k from £58k in H122, primarily driven by a £320k payment from Fosun Pharma. The company reduced its operating losses to £4.3m from £6.1m, largely due to decreased clinical trial costs following a strategic shift towards its exosome platform, CustomEx. With a gross cash position of £10.5m, ReNeuron anticipates funding operations into Q4 CY23. The company's valuation stands at £44.2m, or 77p per share, affected by updated financial model assumptions.

EyeGate Pharmaceuticals announced the acquisition of Bayon Therapeutics, adding a portfolio of vision-restoring small molecules to its development pipeline. Effective October 21, 2021, Eric J. Daniels, MD, MBA, has been appointed as Chief Development Officer to lead this initiative. The acquisition includes the promising small molecule B-203, designed to restore vision in patients with inherited retinal diseases. EyeGate will issue 33,798 common shares to Bayon's stakeholders and may pay up to $7.1 million more based on clinical milestones.

EyeGate Pharmaceuticals (NASDAQ: EYEG) will provide a corporate update at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. President and CEO, Brian M. Strem, Ph.D., will participate in one-on-one investor meetings. The presentation will be available on-demand via the conference portal starting at 7:00 a.m. ET on September 13. EyeGate is developing ophthalmic products, including PP-001, a next-generation immuno-modulatory drug, and Ocular Bandage Gel for corneal wound repair.

EyeGate Pharmaceuticals (NASDAQ: EYEG) has successfully completed the enrollment of 21 patients for its Phase 2 proof-of-concept study of PP-001, targeting ocular surface inflammation, including dry eye disease. This milestone follows positive Phase 1 safety data and sets the stage for topline results expected in Q4 2021. PP-001 is an innovative immune-modulating molecule designed to enhance treatment specificity and reduce side effects associated with traditional DHODH inhibitors. An IND filing for dry eye disease is also anticipated in the same quarter.

EyeGate Pharmaceuticals (NASDAQ: EYEG) reported its Q2 2021 financial results and corporate updates, highlighting significant advancements in its clinical pipeline. Key developments include the progress of PP-001, an innovative treatment for dry eye disease, which successfully completed a Phase 1 safety study, and plans for a pre-IND meeting with the FDA in Q3 2021. EyeGate raised approximately $9.7 million through a direct offering and private placement. Q2 research and development expenses rose to $1.440 million, up from $0.631 million in the previous year, primarily due to the Panoptes acquisition.

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) has successfully closed a registered direct offering of 4,668,844 shares of common stock at $2.3025 per share, raising approximately $10.75 million. Additionally, investors received warrants to purchase 2,334,422 shares at an exercise price of $2.24. The funds will support operations, including clinical trials and general corporate purposes. The offering was conducted under the effective shelf registration statement, ensuring compliance with SEC regulations.

EyeGate Pharmaceuticals (NASDAQ: EYEG) announced a registered direct offering of 4,668,844 shares at $2.3025 per share, aiming for gross proceeds of approximately $10.75 million. The transaction includes unregistered warrants for 2,334,422 additional shares, with an exercise price of $2.24. Funds will support clinical trials, working capital, and R&D efforts. The offering will close around August 11, 2021, subject to standard conditions. The shares are offered under a previously declared effective registration statement, while the warrants remain unregistered.

EyeGate Pharmaceuticals has appointed Brian M. Strem, Ph.D., as the new President and CEO. Strem, previously co-founder of Bayon Therapeutics, brings extensive expertise in ophthalmic drug development. The company also signed a non-binding letter of intent to acquire Bayon, focusing on innovative therapies to restore vision through photoswitch molecules designed for degenerative retinal diseases. The acquisition could involve payment of 50,000 shares plus up to $7.1 million based on milestones. However, there is no guarantee a definitive agreement will be reached.

EyeGate Pharmaceuticals (NASDAQ: EYEG) announced dosing of the first patient in a phase II proof-of-concept study for its lead drug candidate, PP-001, aimed at treating ocular surface inflammation, including dry eye disease. The randomized study, taking place in Vienna, Austria, involves 21 patients receiving either PP-001 or a placebo over 12 days. Positive preclinical and phase 1 data have bolstered expectations for PP-001, which is designed to mitigate off-target effects associated with existing DHODH inhibitors. Topline results are expected by Q4 2021.